Eton Pharmaceuticals, Inc. Announces Sixth Amendment to Credit Agreement with SWK Funding LLC – Key Financing Terms Improved

Key Highlights for Investors

• Interest Rate Reduction: The interest rate on the company’s credit facility has been reduced from SOFR (Secured Overnight Financing Rate) + 6.75% to SOFR + 6.55%.
• SOFR Floor Lowered: The SOFR floor was cut from 5.0% to 2.75%, lowering the minimum interest rate the company will pay.
• Extended Interest-Only Period: Eton Pharmaceuticals now has an extended interest-only period, allowing the company to delay principal payments until November 2026 (previously earlier). The company can also choose to start principal payments in May 2026 but is not required to.
• No Fees Paid for Amendment: Eton paid no fees to SWK Funding LLC for this amendment, which is favorable compared to market practices where amendment fees are common.
• Unchanged Maturity Date: The overall maturity date of the credit agreement remains December 2027, so no acceleration of debt obligations has taken place.

Detailed Overview of the Announcement

On April 9, 2026, Eton Pharmaceuticals, Inc. (“Eton” or “the Company”) entered into a sixth amendment to its credit agreement with SWK Funding LLC (“SWK”). This amendment represents a significant development in Eton’s capital structure and financial commitments, with direct implications for its liquidity, interest expenses, and cash flow flexibility.

Interest Rate & SOFR Floor: The reduction in the credit facility’s interest rate lowers Eton’s borrowing costs. The SOFR floor’s reduction is particularly noteworthy in the current interest rate environment, as it allows Eton to benefit from lower base rates, minimizing overall interest expense.

Interest-Only Period Extension: By extending the interest-only period, Eton can preserve more cash for operational needs, business development, or potential growth initiatives. This flexibility in cash management may be critical for the company’s ongoing strategies, especially in the competitive pharmaceutical landscape.

Optional Principal Payment: The company has the option, but not the obligation, to begin principal payments in May 2026. If Eton wishes to conserve liquidity, it can defer these payments until November 2026 without penalty.

No Amendment Fees: The absence of any amendment fees paid to SWK can be interpreted as a sign of a strong relationship between Eton and its lender, or as a reflection of Eton’s improved credit standing and negotiation position.

Debt Maturity: The maturity date remains at December 2027, meaning the company’s overall debt timeline is unchanged, providing stability and predictability for future cash flow planning.

Potential Price-Sensitive Elements

• Reduced Interest Expense: The lower interest rate directly decreases Eton’s interest expense, which could have a positive impact on net income and cash flow. This may enhance shareholder value and could be viewed positively by investors.
• Improved Liquidity: The extension of the interest-only period improves near-term liquidity, allowing the company to allocate resources to growth or strategic initiatives instead of debt service.
• No Immediate Outflows for Amendment Fees: The lack of amendment fees preserves cash and reduces one-off expenses, supporting the company’s financial health.
• Financial Flexibility: The option to defer principal payments provides management with flexibility to respond to opportunities or challenges in the business environment.
• All Terms Publicly Disclosed: Transparency in the agreement amendment and the absence of hidden fees or penalties may also foster investor confidence.

Other Material or Noteworthy Items

• Securities Information: Eton Pharmaceuticals’ common stock (trading symbol: ETON) is listed on the NASDAQ Global Market.
• Emerging Growth Company Status: Eton is not classified as an “emerging growth company” under SEC rules, and has not elected any extended transition periods for complying with new or revised accounting standards.
• Execution: The amendment was executed by James R. Gruber, Chief Financial Officer and Secretary of Eton Pharmaceuticals, Inc.

Implications for Shareholders

The revised credit agreement improves Eton Pharmaceuticals’ financial flexibility and reduces its cost of capital. These changes may enhance the company’s ability to invest in its business, pursue strategic opportunities, and navigate potential periods of market or operational volatility. Investors should monitor how Eton utilizes the increased cash flow flexibility and whether the company’s operating performance reflects the potential benefits of these improved financing terms.

Given these factors, the news may be considered price sensitive, as improvements in liquidity and lower interest expenses can positively impact the company’s earnings, cash flows, and overall valuation.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult their financial advisor before making investment decisions. The information provided is based on public filings as of April 2026 and may be subject to change.

View Eton Pharmaceuticals, Inc. Historical chart here